Skip to main content
. 2023 Jun 28;12(13):4339. doi: 10.3390/jcm12134339

Figure 1.

Figure 1

Comparison of serum profiles of pro-GN (A), S100A12 (B) and PTX3 (C) in the group of patients with UC before, as well as after, a year of Adalimumab therapy, and in healthy individuals *—p < 0.001; **—p < 0.005; C—healthy individuals; UC0—patients with UC before biological treatment; UC1—patients with UC after a year of treatment.